Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Thromboxane prostaglandin receptor antagonist and carotid atherosclerosis progression in patients with cerebrovascular disease of ischemic origin: a randomized controlled trial.

Bots ML, Ford I, Lloyd SM, Laurent S, Touboul PJ, Hennerici MG; Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin With Terutroban in Patients With a History of Ischemic Stroke or Transient Ischemic Attack Vascular Ultrasound Study Investigators.

Stroke. 2014 Aug;45(8):2348-53. doi: 10.1161/STROKEAHA.114.004775. Epub 2014 Jun 24.

2.

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.

Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group.

Arch Neurol. 2012 Oct;69(10):1259-69.

PMID:
22751847
3.

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.

Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group.

Lancet Neurol. 2012 May;11(5):420-8. doi: 10.1016/S1474-4422(12)70056-X. Epub 2012 Apr 10. Erratum in: Lancet Neurol. 2012 Aug;11(8):658.

PMID:
22494956
4.

Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.

Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoüe A, Fratacci MD; PERFORM Study Investigators.

Lancet. 2011 Jun 11;377(9782):2013-22. doi: 10.1016/S0140-6736(11)60600-4. Epub 2011 May 25. Erratum in: Lancet. 2011 Jul 30;378(9789):402.

PMID:
21616527
5.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.

6.

[Hypertension and its therapy in the acute phase of stroke].

Káposzta Z, Rácz K.

Ideggyogy Sz. 2009 May 30;62(5-6):164-7. Review. Hungarian.

PMID:
19579664
7.

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.

Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici MG, Mattle HP, Rothwell PM; PERFORM Study Investigators.

Cerebrovasc Dis. 2009;27(5):509-18. doi: 10.1159/000212671. Epub 2009 Apr 16. Erratum in: .

PMID:
19372653
8.

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.

Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH; Ustekinumab MS Investigators.

Lancet Neurol. 2008 Sep;7(9):796-804. doi: 10.1016/S1474-4422(08)70173-X.

PMID:
18703004
9.

[Insomnia and cerebral hypoperfusion].

Káposzta Z, Rácz K.

Orv Hetil. 2007 Nov 18;148(46):2163-6. Review. Hungarian.

PMID:
17988972
10.

Antiplatelet therapy in ischemic stroke.

Pongrácz E, Káposzta Z.

Expert Rev Neurother. 2005 Jul;5(4):541-9. Review.

PMID:
16026237
11.

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.

Sidhu JS, Kaposzta Z, Markus HS, Kaski JC.

Arterioscler Thromb Vasc Biol. 2004 May;24(5):930-4. Epub 2004 Mar 4.

12.

S-nitrosoglutathione reduces asymptomatic embolization after carotid angioplasty.

Kaposzta Z, Clifton A, Molloy J, Martin JF, Markus HS.

Circulation. 2002 Dec 10;106(24):3057-62.

13.

Online automated detection of cerebral embolic signals from a variety of embolic sources.

Cullinane M, Kaposzta Z, Reihill S, Markus HS.

Ultrasound Med Biol. 2002 Oct;28(10):1271-7.

PMID:
12467853
14.

Asymptomatic embolisation in non-valvular atrial fibrillation and its relationship to anticoagulation therapy.

Tinkler K, Cullinane M, Kaposzta Z, Markus HS.

Eur J Ultrasound. 2002 Jun;15(1-2):21-7.

PMID:
12044849
15.

Switching off embolization from symptomatic carotid plaque using S-nitrosoglutathione.

Kaposzta Z, Martin JF, Markus HS.

Circulation. 2002 Mar 26;105(12):1480-4.

16.

L-arginine and S-nitrosoglutathione reduce embolization in humans.

Kaposzta Z, Baskerville PA, Madge D, Fraser S, Martin JF, Markus HS.

Circulation. 2001 May 15;103(19):2371-5.

17.

[Cerebral deep vein thrombosis associated with rectal cancer].

Tóth L, Szakáll S, Káposzta Z, Udvardy M.

Orv Hetil. 2000 Nov 12;141(46):2493-6. Review. Hungarian.

PMID:
11126682
18.

Evaluation of new online automated embolic signal detection algorithm, including comparison with panel of international experts.

Cullinane M, Reid G, Dittrich R, Kaposzta Z, Ackerstaff R, Babikian V, Droste DW, Grossett D, Siebler M, Valton L, Markus HS.

Stroke. 2000 Jun;31(6):1335-41.

19.

Cerebrovascular reserve capacity in patients with hyperlipidemia.

Kerenyi LL, Fulesdi B, Ficzere A, Kaposzta Z, Valikovics A, Paragh G, Csiba L.

J Clin Ultrasound. 2000 Mar;28(3):115-21.

PMID:
10679697
20.

Clinical application of asymptomatic embolic signal detection in acute stroke: a prospective study.

Kaposzta Z, Young E, Bath PM, Markus HS.

Stroke. 1999 Sep;30(9):1814-8.

Supplemental Content

Loading ...
Support Center